{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:39:11Z","timestamp":1721831951327},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The aim of this prospective phase II study was to evaluate the efficacy and safety of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with metastatic castration-na\u00efve prostate cancer (mCNPC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>Patients with histologically-proven, previously-untreated mCNPC received ADT plus docetaxel, 40\u2009mg\/m<jats:sup>2<\/jats:sup>. Docetaxel was repeated every 2 weeks, up to 12\u2009cycles. Endpoints included castration-resistant prostate cancer (CRPC)-free survival, prostate-specific antigen (PSA) response, and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 42 patients were registered and analyzed for final outcomes. Of the 42 patients, 36 (86%) completed the 12 planned cycles of docetaxel plus ADT. During a median follow up of 25\u2009months, all but two patients (95%) achieved a PSA response with a nadir PSA level of 0.42\u2009ng\/ml (range 0.01\u20131280.87). The median CRPC-free survival was 26.4\u2009months (95% confidence interval [CI] 20.9\u201332.0) with a one-year CRPC-free rate of 79% (33 patients, 95% CI 66\u201391). Multivariable analysis revealed that the performance status of the Eastern Cooperative Oncology Group 0 was independently associated with longer CRPC-free survival (hazard ratio [HR] 0.27, 95% CI 0.07\u20130.99). The most common adverse events of any grade were anemia (95%), followed by nail changes (33%), fatigue (29%), and oral mucositis (26%). Severe (grade 3 or higher) adverse events were infrequent: pneumonitis (<jats:italic>n<\/jats:italic>\u00a0=\u20092), diarrhea (<jats:italic>n<\/jats:italic>\u00a0=\u20091), and neutropenia (<jats:italic>n<\/jats:italic>\u00a0=\u20091).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results suggest that biweekly docetaxel plus ADT is feasible, and clinical efficacy does not seem to be compromised compared to a standard triweekly docetaxel 75\u2009mg\/m<jats:sup>2<\/jats:sup> plus ADT regimen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09018-6","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T01:02:26Z","timestamp":1638147746000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-na\u00efve prostate cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Seonggyu","family":"Byeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwang Gyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Il","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Soo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Moo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"9018_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4143\/crt.2020.206","volume":"52","author":"S Hong","year":"2020","unstructured":"Hong S, Won YJ, Park YR, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020;52:335\u201350.","journal-title":"Cancer Res Treat"},{"key":"9018_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/1477-3163.83937","volume":"10","author":"PE Lonergan","year":"2011","unstructured":"Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20.","journal-title":"J Carcinog"},{"key":"9018_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"9018_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"9018_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"9018_CR6","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79:263\u201382.","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"9018_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334.","journal-title":"Ann Oncol"},{"key":"9018_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992\u20132003.","journal-title":"Ann Oncol"},{"key":"9018_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117\u201324.","journal-title":"Lancet Oncol"},{"key":"9018_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12894-017-0253-z","volume":"17","author":"HS Kim","year":"2017","unstructured":"Kim HS, Lee JY, Lee SJ, et al. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. BMC Urol. 2017;17:63.","journal-title":"BMC Urol"},{"key":"9018_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12894-019-0463-7","volume":"19","author":"SE Yoon","year":"2019","unstructured":"Yoon SE, Kim Y, Cho J, et al. A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer. BMC Urol. 2019;19:30.","journal-title":"BMC Urol"},{"key":"9018_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"9018_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","volume":"19","author":"E Schaeffer","year":"2021","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate Cancer, version 1.2021. J Natl Compr Cancer Netw. 2021;19:134\u201343.","journal-title":"J Natl Compr Cancer Netw"},{"key":"9018_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235\u201348.","journal-title":"Ann Oncol"},{"key":"9018_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jjco\/hyw193","volume":"47","author":"N Tanaka","year":"2017","unstructured":"Tanaka N, Nishimura K, Okajima E, et al. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Jpn J Clin Oncol. 2017;47:247\u201351.","journal-title":"Jpn J Clin Oncol"},{"key":"9018_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4111\/icu.2019.60.3.195","volume":"60","author":"WA Kwon","year":"2019","unstructured":"Kwon WA, Joung JY, Lee JE, et al. Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: a retrospective study. Investig Clin Urol. 2019;60:195\u2013201.","journal-title":"Investig Clin Urol"},{"key":"9018_CR17","first-page":"1997","volume":"21","author":"T Taguchi","year":"1994","unstructured":"Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho. 1994;21:1997\u20132005.","journal-title":"Gan To Kagaku Ryoho"},{"key":"9018_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4143\/crt.2010.42.1.12","volume":"42","author":"JL Lee","year":"2010","unstructured":"Lee JL, Kim JE, Ahn JH, et al. Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat. 2010;42:12\u20137.","journal-title":"Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09018-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T01:02:34Z","timestamp":1638147754000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9018"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09018-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of Samsung Medical Center (SMC 2017\u201301\u2013005-005, Seoul, Korea). All patients provided written informed consent. All study procedures were conducted in accordance to good clinical practice, and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1281"}}